menu search

viracta therapeutics to present at the jefferies healthcare conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onc...

May 31, 2023, 8:15 pm

viracta therapeutics to present at the rbc capital markets global healthcare conference

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onco...

May 11, 2023, 4:05 pm

viracta therapeutics to present at the stifel 2023 targeted oncology days

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) — viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision o...

April 19, 2023, 8:30 pm

viracta therapeutics to present at the 33rd annual oppenheimer healthcare conference

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision on...

March 8, 2023, 4:05 pm

viracta therapeutics announces first clinical response in epstein-barr virus-positive (ebv+) solid tumor setting and outlines key 2023 clinical objectives

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...

January 8, 2023, 6:00 pm

viracta therapeutics announces preliminary dose-ranging data from the phase 1b/2 trial of nana-val in advanced epstein-barr virus-positive (ebv+) solid tumors at the esmo immuno-oncology congress

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to d...

November 30, 2022, 11:10 pm

viracta therapeutics to present at the 21st annual needham virtual healthcare conference

SAN DIEGO , April 7, 2022 /PRNewswire/ -- viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision onco...

April 7, 2022, 10:13 am


Search within

Pages Search Results: